MTTI Lands $3.17 Million NCI Grant to Advance Lung Cancer Drug
WEST CHESTER, PA — Molecular Targeting Technologies, Inc. secured a $3.17 million, five-year National Cancer Institute grant to advance an experimental radiopharmaceutical toward potential clinical testing in patients with non-small …
MTTI Lands $3.17 Million NCI Grant to Advance Lung Cancer Drug Read More